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ABSTRACT 
Introduction: In western countries, 6-12% of all pregnancies end preterm, i.e. before 37 
weeks of gestation. After the introduction of antenatal corticosteroids and improvements of 
neonatal intensive care, survival rates for children born preterm have increased worldwide. 
In Sweden, 80% of infants born extremely preterm, i.e. before 28 weeks of gestation, 
survive. There is, however, an association between preterm birth and later sequelae. 
Pulmonary complications, such as bronchopulmonary dysplasia (BPD), may result in lung 
function impairment later in life. It has also been demonstrated that a significant proportion, 
around 20-25%, of patients with chronic obstructive pulmonary disease (COPD) have never 
smoked, suggesting other risk factors for developing chronic airway obstruction in 
adulthood. As there are now more survivors reaching adult life, individuals born preterm 
are expected to be an increasing group of patients in the future, contributing to the non-
smoking proportion of patients with COPD. The overall aim of this thesis was therefore to 
extensively characterise clinical, functional and mechanistic aspects of pulmonary 
outcomes in adolescence and in adult age in individuals born preterm with and without 
BPD. 
 
Patients and methods: Individuals born before 32 weeks of gestation between 1992 and 
1998 in Stockholm County were investigated both in adolescence (n= 51) and at adult age 
(n= 49). Half of the individuals born preterm had a diagnosis of BPD. In adult age two 
control groups of patients with allergic asthma (n= 23) and healthy individuals (n=24) were 
included. Information on perinatal data, medical history and health related quality of life 
(HRQoL) was collected.  Lung function was measured using dynamic spirometry, body 
plethysmography diffusing capacity for carbon monoxide (DLCO), impulse oscillometry 
(IOS) and lung clearance index (LCI) for ventilation inhomogeneity. Bronchoscopy was 
performed in adults (mean age 20.0 years) including sampling of the large (bronchial 
wash), and small airways (bronchoalveolar lavage, BAL).  
 
Results: Both adolescents and adults with BPD demonstrated airway obstruction in 
contrast to individuals born preterm without BPD, but both groups had more airway hyper-
responsiveness compared to healthy controls. In adulthood, the preterm group had lower 
DLCO irrespective of BPD status, but only those with BPD had signs of inhomogeneous 
ventilation. Adults with BPD reported fewer physical symptoms than asthmatic controls, 
despite lower lung function in the former group. Both preterm groups reported lower scores 
in the mental component summary of a questionnaire compared to healthy controls. In 
contrast to the asthmatic group, no eosinophilic inflammation was seen in the preterm 
group. In BAL, the  preterm BPD group showed an increased proportion of activated 
cytotoxic T cells (CD8
+
), a decreased proportion of T helper cells (CD4
+
), and, as a 
consequence, a decreased CD4/CD8 ratio, when compared to the healthy controls. T-cell 
subsets in BAL correlated with measures of airflow limitation in individuals with BPD.  
Further, in bronchial wash, elevated proportion of lymphocytes was observed. A correlation 
of lymphocyte count with measures of airflow obstruction in the preterm born individuals 
was seen predominantly in males.  
 
Conclusions: Individuals born preterm with a history of BPD have obstructive airflow 
limitations engaging the small airways. Lymphocytes may have a sex-specific role, as an 
increased amount was found in the large airways in males with BPD. The increased 
proportion of cytotoxic (CD8
+
) T cells in BAL resemble features of COPD, and are 
compatible with the hypothesis that T-cells may play a mechanistic role in development of 
airway obstruction in adults with a history of BPD.  
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1 INTRODUCTION 
In western countries, approximately 6 to 12 per cent of all pregnancies end preterm (before 
37 weeks of gestation).
1,2
 After the introduction of antenatal corticosteroids 35 years ago 
and improvement of neonatal intensive care, survival rates after preterm birth have 
increased worldwide.
3
 In Sweden 80% of infants born extremely preterm (before 28 weeks 
of gestation) survive.
4
 There is an association between preterm birth and later complications 
during the neonatal period, during childhood and into adult life. For instance, preterm birth 
is associated with development of obstructive lung disease, cardiovascular diseases, 
diabetes mellitus and cognitive disorders.  Individuals with airway obstruction associated 
with preterm birth are expected to be a growing group of patients in the future since there 
are now more survivors reaching adult life.
5-7
 It is difficult to identify which children born 
preterm who are at risk for developing chronic lung disease in adulthood as there currently 
are no known biomarkers to evaluate lung damage due to preterm birth. Children born 
preterm with respiratory problems are treated with bronchodilators, inhaled corticosteroids 
and leukotriene receptor antagonists even though this is not evidence based medicine.
8,9
 
Very little is known if there is an ongoing inflammation or presence of structural changes in 
the lungs and how this is related to functional parameters or clinical symptoms. It is 
therefore important to characterise both clinic/symptoms and molecular changes in the lung 
in children born preterm in order to better understand the connection between perinatal 
factors and chronic lung disease in adulthood.  
2 BACKGROUND 
2.1 THE RESPIRATORY SYSTEM 
The respiratory system includes the airway tree, the lung parenchyma and pulmonary 
vessels. The main function is to provide oxygen to the body and to remove carbon dioxide 
from the bloodstream. The airway tree has approximately 23 generations of branches which 
are divided into conducting airways generation (the first 15 generations), and intra-acinar 
airways. In the conducting airways there is no gas exchange and the lining consists of 
bronchial epithelial cells. The term “small airways” refers to airways from generation eight 
and more peripheral and with a diameter of 2 mm or less in adults. Gas exchange occurs 
from the intra-acinar airways where the alveoli begin to appear. The alveoli have a thin one 
cell layer wall and are surrounded by a network of capillaries allowing exchange of oxygen 
and carbon dioxide. In the last generation alveoli forms blind ending alveolar sacs.
10
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2.2 THE NORMAL LUNG DEVELOPMENT 
The development of the normal lung is a process that begins in the embryonic phase and 
continues after birth into childhood.
11,12
 Furthermore, there are new data suggesting that 
lung development is an even longer ongoing process proceeding into adolescence and early 
adulthood.
13
 
 
The embryonic phase is the first of the five phases of lung development and occurs during 
week 4-7 of gestation. This phase begins with the formation of a groove in the ventral lower 
pharynx, sulcus laryngotrachealis. Within a couple of days buds form the lower parts, the 
lung primordia. The development continues with further subdivision into the two main 
bronchi where the left one is directed more laterally than the larger one on the right side, 
which is directed more caudally. The subsequent lung growth continues to be asymmetric 
with formation of three endodermal buds on the right side and two on the left side. These 
buds will further divide into the segments of the individual pulmonary lobes at the end of 
the embryonic phase. The vasculogenesis occurs within the immature mesenchyme.  
The next phase that occurs is the pseudoglandular phase between gestational weeks 5-17. 
All the phases are somewhat overlapping in the beginning and at the end of each phase. In 
this phase the lung resembles the development of a tubule-acinus gland. The bronchial buds 
are now undergoing a rapid dichotomous branching and the entire air-conducting bronchial 
tree up to the terminal bronchiole (i.e. the first16 generations) is formed. At the end of this 
phase there are up to 20 generations present in some parts of the lung. These lower 
generations represent respiratory ducts. At the 10
th
 week of gestation cartilage, smooth 
muscle cells and bronchial glands can be found in the bronchial walls. The cells coating the 
air-conducting bronchial tree are initially cubic epithelia which are the precursor cells of the 
ciliated epithelium and of the secretory cells. The first ciliated epithelial cells occur in the 
13
th
 week of gestation. Type II pneumocytes appears in the respiratory part of the terminal 
bronchiole. The epithelium of the maturing lung then begins to produce lung fluid.
11
 
During the canalicular phase (weeks 16-27), canaliculi expand out of the terminal 
bronchiole. They represent the proper respiratory part, the pulmonary parenchyma. At the 
terminal bronchioles the acini are formed with respiratory bronchiole, the alveolar ducts 
and later the alveolar sacculi. Along the acinus a massive migration of capillaries into the 
mesenchyme occurs.  The flattened type I pneumocytes develop from the cubic type II 
pneumocytes. This latter step, with differentiation of sufficient levels of type II 
pneumocytes to type I pneumocytes and proliferation of capillaries is crucial for survival of 
infants born preterm. Synthesis and storage of surfactant can be seen in the type II 
 13 
 
pneumocytes.  In the saccular phase from gestation weeks 24-38 cluster of sacs develop on 
the terminal bronchiole. They are the last generation of conducting airways and also the 
terminal respiratory part of the bronchial tree. In the succuli type I and II pneumocytes 
cover the surface. The type II pneumocytes start to secrete surfactant into the foetal lung 
fluid. The primary septa between sacculi are thick and contain a double capillary network. 
The interstitial space contains a great amount of cells compared to the proportion of 
collagen and elastic fibres. Interstitial fibroblast starts to produce extracellular material at 
the end of this phase. The alveolar phase is the last phase of lung development. The first 
part of this phase takes place from gestational week 36 to three years of age, when the 
alveoli are formed by secondary septa that divide the succuli into thin walled structures 
with a capillary bed. The thin layers enhance the gas exchange between the air and the 
blood. The one layer epithelium of the alveoli consists of type I and type II pneumocytes. 
Recent studies suggests that the process is continued with a second phase, with a refining of 
the capillary bed between the alveoli to a single layer of capillaries continuing into early 
adulthood.
12
 
 
 
Figure 1. Development of the lung (blue), the airways (black), and the arteries (red). 
Reproduced from Schittny JC.
12
 With permission from Springer; Cell and Tissue Research, 
2017. 
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2.3 THE IMMUNE SYSTEM  
 The innate immune system  2.3.1
The innate immune system of the airways and the lung consists of cells and mediators 
serving as the first line defence against invasion of different pathogens. It can act fast, 
immediate or within hours, when recognizing a potential pathogen. The structural cells 
involved to produce a barrier to infections are ciliated cells, mucus-secreting goblet cells, 
club cells producing antimicrobial compounds, and basal cells.
14
 Innate immune cells in the 
tissue are including macrophages, dendritic cells, neutrophils, eosinophils, monocytes, 
innate lymphoid cells (ILC), natural killer cells (NK), and mast cells (Figure 2).
15
 
 
 
Figure 2. Cells involved in the innate and adaptive immune system.  
Reprinted by permission from Springer Nature: Nature Reviews Cancer, Cytokines in 
cancer pathogenesis and cancer therapy, Danoff G, 2004 
 
 The adaptive immune system 2.3.2
The adaptive immune response is antigen specific but slower, and has evolved to recognize 
both self- and nonself- antigens. It consists of lymphocytes and their products (Figure 2). 
Adaptive immune response depends on receptors that are tailored to be specific. The 
receptors are selected through a process of recombination of different gene segments. The 
 15 
 
adaptive immune system contains immunologic memory which gives a more effective 
response to multiple exposures of the same antigen.
16
 
 T cells 2.3.2.1
Progenitor T cells originate from the bone marrow and migrate to the thymus where they 
mature. T cells express specific antigen-binding receptors on their surface called T-cell 
receptors (TCR). T cells demand action from antigen presenting cells (APC) such as 
dendritic cells, macrophages, B cells, fibroblasts, and epithelial cells to be able to recognize 
specific antigens. When receiving an appropriate signal the T cell can proliferate and 
differentiate rapidly. Bound to the surface of APC there are proteins called major 
histocompability complex (MHC). These are either MHC class I (in humans also called 
human leukocyte antigen [HLA] A, B and C) which are expressed on all nucleated cells, or 
MHC class II (also called HLA DP, DQ and DR) which are only expressed by some cells in 
the immune system for instance macrophages, dendritic cells and B cells.  The cells 
expressing MHC class I mainly present peptides from viruses and aberrant cells, thereby 
enabling the activation of cytotoxic T cells (CD8
+
 cells). Activation of CD
+
8 cells is 
followed by clonal expansion which leads to production of effector cells. Effector cells 
activate apoptotic cell death within minutes after binding to complex of peptides bound to 
MCH class I on the target cell. This process involves exocytosis of granules including 
granzymes and perforins.  Another mechanism of apoptosis is driven by expansion of the 
Fas ligand on the CD8
+
 cells. Apoptosis of the target cell is triggered when this ligand binds 
to Fas (CD95).
17
  The cells expressing MHC class II internalize and degrade extracellular 
pathogens for example bacteria and then display peptides to T- helper (Th) cells (CD4
+
 
cells). CD4
+
cells are unable to directly kill infected cells or clear pathogens. Instead they 
work by releasing cytokines and further conduct other cell types, including the APCs to 
perform these tasks. The activation  of CD4
+
 cells lead to differentiation into several types 
of effector cells of which Th1, Th2 and Th17 subsets are the most common. The 
characteristics of Th1 response is secretion of interferon (IFN)-γ and interleukin (IL)-2 
targeting macrophages to act in defence against intracellular pathogens. Typical for the Th2 
response is secretion of IL-4, IL-5, IL-6, IL-9, IL-10 and IL-13 which target eosinophils in 
the defence against parasites (helminths) whereas the Th17 produces IL-17 and IL-22 to 
engage neutrophils to work against extracellular pathogens. There is a subset of CD4
+
 T 
cells called regulatory T Cells (Treg) that possesses immunoregulatory functions to 
suppress inflammation and inhibit autoimmunity. The Tregs express a transcription factor 
called forkhead box P3 (FOXP3) and a bright expression of the surface marker CD25.
18,19
 
 16 
 
The γδ T cells are abundant in epithelia in the gut but represent only around 5% of all T 
cells. They neither express CD4 nor CD8.
17
 Natural killer T cells (NK-T cells) are a small 
population, less than 5% of all T cells, which express both αβTCR and the same markers as 
NK cells such as CD56 and CD16.
20
 Activated NK-T cells can fast produce high amounts 
of cytokines.
17
 
 B cells 2.3.2.2
The B cells derive from hematopoietic stems cells in the bone marrow where they mature 
and develop the ability to generate an antigen specific humoral immune response. The 
response involves production of antibodies that can neutralize toxins, opsonization of 
pathogens promoting phagocytosis, complement activation, and cell mediated cytotoxicity.  
Proteins, lipids, carbohydrates, macromolecules and smaller chemicals can be recognized 
by B cells directly, without the need for APCs, by their unique cell surface bound 
antibodies. When activated by an antigen the B cells proliferate and differentiate into 
plasma cells secreting antibodies, or into memory B cells. The memory B cells are long-
lived and have a rapid response when coming across the same antigen again resulting in fast 
production of antibodies and elimination of the targets. The plasma cells undergo apoptosis 
when the targets are eliminated. Thus, they are short lived; they are very effective as they 
produce copious amounts of antibodies.
16
 B cells produce five major types of antibodies: 
Immunoglobulin (Ig)A, IgD, IgE, IgG and IgM. IgG can be further sub-classified. The 
different classes of antibodies have contrasting functions and distinguish diverse pathogens.  
B cells also act by cell-mediated immunity without any involvement of antibodies but 
through activation of antigen-specific cytotoxic T cells, macrophages, NK cells and thereby 
stimulation of cytokine production. The cell mediated immunity is directed to effective 
elimination of virus-infected cells and cancer cells but also has a role in the defence against 
intracellular bacteria, protozoes, and fungus.  
 Microbiota in the airways  2.3.3
Development of the microbiota after birth has an impact on the immune system and future 
health. It is influenced by many factors, such as mode of delivery, breast feeding, genetics, 
environmental factors, and treatment with antibiotics.
21,22
 The microbiota of the airways 
serves as protection against colonization by pathogens. The respiratory microbiota might 
also play a role in the homeostasis of respiratory physiology and immunity.
23
 However, the 
precise role of the microbiota remains to be investigated. 
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2.4 FACTORS AFFECTING LUNG DEVELOPMENT 
 Maternal/paternal factors 2.4.1
Maternal smoking during pregnancy is associated with poor lung function at birth, during 
childhood and in early adulthood.
24
 Infants born preterm exposed to maternal smoking in 
utero have an increased risk of developing BPD.
25,26
 In experimental animal models the 
effects of nicotine on lung development have been demonstrated to cause thicker alveolar 
walls, increased airway smooth muscle and collagen deposition, and airway hyper 
responsiveness with airflow restriction.
27,28
 Other risk factors for BPD include genetics and 
hereditary factors. In a large population-based cohort Gage et al. found that children born 
preterm to asthmatic mothers who did not receive antenatal steroids had an increased risk of 
developing BPD.
29
 Influence of genetics has been shown by Bhandari et al in a twin study 
where they compared the risk of developing BPD, necrotizing enterocolitis and 
intraventricular haemorrhage in pairs of mono- and dizygotic twins born ≤ 32 weeks of 
gestation. They found that genetic factors explained 53% of the risk to develop BPD, after 
adjusting for covariates.
30
 Lavoie et al. evaluated mono- and dizygotic twins born ≤ 30 
weeks of gestation in Canada and demonstrated a substantial genetic contribution to 
moderate-to-severe BPD.
31
 Research has also been focused to identify associations with 
BPD involving molecules or pathways connected to lung development, inflammation, 
fibrosis angiogenesis oxidative stress or tissue injury and repair.
32-34
 However, many of the 
associated single nucleotide polymorphisms in candidate genes have not been confirmed in 
genome-wide association studies on patients with BPD.
35,36
 
 Pre-/peri-/post-natal factors 2.4.2
 Preterm birth 2.4.2.1
Preterm birth is defined as delivery before 37 weeks of gestation. Very preterm infants are 
born <32 weeks and extremely preterm infants <28 weeks of gestation. According to the 
Swedish National Board of Health and Welfare statistics, 5-6 % of all pregnancies in 
Sweden end preterm (<37 weeks), about 1% end very preterm and 0.3-0.4% end extremely 
preterm.
37
  Due to preterm birth, lung maturation is disrupted during the canalicular and 
saccular/early alveolar phases of normal lung development, a process that is supposed to 
take place before birth. The level of surfactant is insufficient and the structures of the lungs, 
i.e. airways, vasculature and interstitium, are immature. Antenatal glucocorticoid steroids 
given to mothers at risk of preterm delivery has improved survival of very preterm infants 
the last decades. Glucocorticoids accelerate lung maturation in the foetus which reduces the 
 18 
 
risk of developing respiratory distress syndrome.  It also has the effect of reducing the risk 
for intraventricular haemorrhage and necrotizing enterocolitis in preterm born infants and 
reduces mortality in the group.
38,39
  
 Respiratory distress syndrome (RDS) 2.4.2.2
In infants born preterm respiratory distress syndrome (RDS) is a common condition with 
inadequate gas exchange. Insufficient levels of surfactant in the alveolus causes RDS.
40
 The 
incidence increases with decreasing gestational age (GA). The definition is based on 
symptoms of respiratory distress (retractions, grunting and tachypnoea), increasing demand 
for supplemental oxygen and typical chest X-ray findings without any evident other 
conditions.
40,41
 RDS is a common cause for the need of nasal continuous positive airway 
pressure (NCPAP) or mechanical ventilation. RDS is in modern neonatal care treated by 
intratracheal administration of exogenous surfactant. 
 Bronchopulmonary Dysplasia (BPD) 2.4.2.3
Some of the infants with RDS at birth will eventually develop bronchopulmonary dysplasia 
(BPD). Approximately 10-30% of infants born younger than GA 30 weeks and with a birth 
weight (BW) under 1000 g will develop this condition.
42
 Bronchopulmonary dysplasia is 
often explained as a developmental condition with pathogenesis being linked to immature 
lungs, inflammation, barotrauma and volutrauma resulting from the use of mechanical 
ventilators and oxidative stress due to the need for supplemental oxygen.
43
 Historically, 
BPD, now referred to as “old BPD” was associated with inflammation, parenchymal 
fibrosis and airway injury. However, the achievements in modern neonatal care have been 
accompanied by a new phenotype with altered disease, where “new” BPD is characterized 
of even more immature lung tissue affected by reparative processes, impaired 
alveolarization, and dysmorphic vascular growth.
44-46
 BPD is currently defined by the need 
for supplemental oxygen in 28 days. It can be further classified as moderate or severe BPD 
based on the level of oxygen need at 36 weeks of gestation (Table 1).
47
 To confirm the 
oxygen requirement at the assessment time point a standardized stepwise oxygen reduction 
challenge test should be performed. A day of treatment with oxygen > 21% is defined as 
more than 12 hours with supplemental oxygen within one day.
 4,5,42
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Table 1. Definition of Bronchopulmonary Dysplasia according to Jobe and Bancalari
47
 
Gestational 
Age 
< 32 weeks ⩾ 32 weeks 
Treatment with oxygen > 21% for at least 28 days plus 
Mild BPD 
Breathing room air at GA 36 
weeks or discharge 
Breathing room air by 56 days postnatal 
age or discharge 
Moderate BPD 
Need for < 30% oxygen at GA 
36 weeks or discharge 
Need for < 30% oxygen at 56 days 
postnatal age or discharge 
Severe BPD 
Need for ⩾ 30% oxygen and/or 
positive pressure, at GA 36 
weeks or discharge 
Need for ⩾ 30% oxygen and/or positive 
pressure, at 56 days postnatal age or 
discharge 
Abbreviations: BPD = bronchopulmonary dysplasia; GA = gestational age 
 Chorioamnionitis 2.4.2.4
Chorioamnionitis is a risk factor for the development of BPD in more than one way. It is a 
major risk factor of premature birth, which in turn is the strongest risk factor of developing 
BPD.
48,49
 It also causes chronic inflammation in the lung due to pro-inflammatory cytokines 
in the amniotic fluid.
50,51
 Chorioamnionitis is characterized by an intrauterine inflammation 
of the choriodecidual space, chorioamniotic membranes, amniotic fluid or the umbilical 
cord. The clinical findings are maternal fever, elevated white blood cell count, tender 
uterus, and by amniotic fluid analyses for positive microbial culture or PCR, elevated 
cytokines (IL-6, tumour necrosis factor α (TNF-α), IL1β and IL-8), or inflammatory cells. 
The histological signs are granulocyte infiltration and occurrence of necrosis in the 
choramnion.
52
 The organisms found in cultures can be single microbes or polymicrobial of 
aerobes and anaerobes generally found in vaginal flora. The most common pathogens 
associated with chorioamnionitis and preterm delivery are Ureaplasma spp.
53-55
 In contrast 
to an increased risk of developing BPD, the inflammation driven by chorioamnionitis seems 
to reduce the incidence of RDS due to earlier lung maturation and induction of surfactant 
production.
56
 It has been difficult to study and establish the consensus of the relationships 
between chorioamnionitis, RDS and BPD because of the complexity with different 
antenatal variables and the postnatal exposures with diverse care strategies that contribute 
to the diagnoses of RDS and BPD. Animal models have provided information on how 
experimental chorioamnionitis can impact the foetal lung.
57
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 Intrauterine growth restriction, small for gestational age  2.4.2.5
Five to fifty percent of infants born preterm are growth restricted or small for gestational 
age (SGA) at birth.
58-60
 Intrauterine growth restriction (IUGR) is diagnosed if the foetus 
does not reach its target weight according to ultrasound estimation for the GA. An 
estimated weight < 10
th
 percentile is a widely used definition. SGA implies a BW less than 
two standard deviations (SD) below the mean according to GA. However, IUGR and SGA 
are not synonymous. IUGR is mirroring a pathological process taken place in utero. An 
infant born SGA has not necessarily suffered from IUGR but could be constitutionally 
small and an infant with only a short period of IUGR is not always born SGA.
61
 According 
to the foetal origin hypothesis an unfavourable intrauterine environment resulting in IUGR 
and/or SGA can affect lung development.
62,63
 Infants born IUGR/SGA have an increased 
respiratory morbidity and mortality during the neonatal period.
64,65
 IUGR/SGA is 
associated with decreased lung function in children and adults.
66-69
 
 Nutrition 2.4.2.6
Infants born extremely preterm are at risk for postnatal growth restriction secondary to 
challenges of delivering optimal nutrition. Despite advances in the use of nutrients for both 
enteral and parenteral use many preterm infants demonstrate growth failure. Nutrition plays 
a critical role in the prevention and management of BPD. Malnutrition can worsen BPD by 
compromising lung growth.
70-72
 Murine models of postnatal growth restriction  have 
described pulmonary vascular remodelling, right ventricular hypertrophy, and an altered 
expression of regulators of lung development including vascular endothelial growth 
factor.
73
 Infants with BPD have been estimated to have a 15% to 25% larger energy need 
than infants without BPD.
74
 Feeding difficulties in these infants can further affect nutrition. 
Initial parenteral nutrition with protein and lipids, and early enteral feeding may help 
decrease the incidence of BPD.
75
 The use of fortified breast milk and/or formula is 
necessary to achieve adequate growth if total daily fluid intake is restricted. Nutritional 
status at 2 years of age is a positive predictor of pulmonary outcomes later in childhood.
76
 
 Respiratory support  2.4.2.7
The practice of mechanical ventilation in preterm infants using adult equipment with 
adapted devices to fit infants started in the beginning of the 1960s. There were many 
problems with the use of ventilators in infants born preterm. The ventilators were too rough 
and they had a large dead space. In addition, they were not able to synchronise with the 
infants’ breathing and it was therefore necessary to sedate and completely paralyse the 
patients. Before the use of endotracheal tubes all patients were tracheotomised.
77
 Despite of 
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the crude treatment, the preterm born patients had a greater chance to survive than before 
but many of them developed the old form of BPD.
45
 
The first ventilator designed exclusively for paediatric and neonatal use was introduced in 
1980. With its introduction infants born preterm could be ventilated on a volume-oriented 
basis for the first time, as the volume was metered and measured more exact. The use of 
mechanical ventilation is a well-known risk factor for BPD. It can cause volutrauma when 
the lungs are inflated with volumes larger than the total lung capacity (TLC), and 
barotrauma occurs when the lung is over-distended with a disarrangement of structural 
elements. This will lead to an inflammatory response and an influx of chemokines and 
cytokines, and a relocation of leukocytes into the lung.
78
 Ventilation with volumes below 
functional residual will lead to collapse and re-expansion of the peripheral airways and 
alveoli, and causes atelectotrauma due to shear stress and injury.
79
 In the last decades, 
different ventilation strategies to prevent or minimize lung injury have arisen. These are 
different modes of synchronized ventilation and volume targeted ventilation.
80
 The use of 
noninvasive ventilation strategies such as nasal continuous positive airway pressure 
(nCPAP) (Figure 3) has been a successful way to reduce the rates of BPD
81-83
, and can 
replace intubation and surfactant as the first line of therapy for many preterm infants.
84,85
 
High-flow nasal cannula (HFNC) is another form of noninvasive respiratory support that 
has become more popular and is recently used with increasing frequency, both as primary 
respiratory support after birth and when weening from mechanical ventilation and 
nCPAP.
86
 
   
  
Figure 3. 
One-day-old girl with nCPAP, 
born preterm at 27 weeks 
gestational age. 
With permission from the 
parents. 
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 Drugs 2.4.2.8
Supplemental oxygen  
Oxygen therapy is one of the most essential drugs used worldwide in neonatal care. 
However, exposure to high concentrations of oxygen contributes to the development of 
BPD. Hyperoxia results in a production of cytotoxic reactive oxygen species which causes 
an acute pulmonary injury characterized by an inflammatory response with destruction of 
the alveolar capillary barrier, followed by cell death.  This process, with a simultaneous 
damage and an attempt to repair, mediated via a variety of factors, results in lung pathology 
that in the end will result in development of BPD in infants born preterm.
87-91
 Animal 
models of oxygen-mediated lung injury have been used in order to address this 
question.
92,93
 
Surfactant 
Exogenous surfactant is an established treatment of preterm infants with RDS. It improves 
gas exchange and survival.
94,95
 There are both natural porcine surfactant and synthetic 
surfactant for commercial use. The use of natural porcine surfactant was developed in 1982 
by the Swedish paediatric pathologist Bengt Robertson and clinical chemist Tore 
Curstedt.
96
 The most common way of administration is as a bolus dose through an 
endotracheal tube that in many cases can be removed soon afterwards (INSURE procedure; 
INtubation, SURfactant, Extubation).
97,98
 Modern minimal invasive approaches have 
evolved where the infant is breathing spontaneously and the surfactant is instilled by a thin 
catheter (LISA; less invasive surfactant administration, or MIST; minimal 
invasive surfactant therapy).
99-101
 
Corticosteroids 
Due to their anti-inflammatory effects post-natal corticosteroids have been evaluated as 
both a preventive strategy and potential treatment of BPD. The  concerns regarding side 
effects of systemic use of corticosteroids such as neurodevelopmental impairment, cerebral 
palsy and death have been confirmed in a recent Cochrane review.
102
 Regarding the use of 
inhaled corticosteroids Shinwell et al showed in a meta-analysis a reduction in the number 
of patients who developed BPD but there were no data available on long term 
neurodevelopmental outcome or later pulmonary morbidity. Both early prevention and later 
treatment use of inhaled corticosteroids was included in the analysis.
103
  Further research is 
needed to evaluate the type of inhaled steroid, timing, formulation, dosage, and method of 
administration that is most appropriate for the prevention and treatment of BPD.
104-106
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Bronchodilators 
Salbutamol /Albuterol is an inhaled β2-agonist that is widely used as a bronchodilator for 
the treatment of BPD. Increased compliance and tidal volumes, as well as decreased 
pulmonary resistance have been documented in infants with BPD. It has been associated 
with short-term improvements in pulmonary resistance and lung compliance secondary to 
bronchial smooth muscle relaxation.
107
 A recent Cochrane review examining the role of 
salbutamol was unable to find sufficient evidence of efficacy in the prevention of BPD. 
Very few well performed studies were addressing this question.
108
 Koch et al stated 
recently that early inhaled bronchodilators did not reduce the risk of BPD and death in 
extremely preterm born infants.
109
 Ipratropium bromide is a muscarinic antagonist resulting 
in bronchodilation, mainly used for treatment of chronic obstructive pulmonary disease 
(COPD) in adults. However, the drug is also used in the treatment of infants with BPD, 
often combined with β2-agonists. Significant improvements in airway resistance and 
compliance have been shown but long-term effects of pulmonary function have not been 
demonstrated.
110-112
  
Caffeine  
Caffeine is the most common used methylxanthine to prevent apnoea of prematurity, but is 
also routinely used among infants born preterm for prevention of BPD.  It has been shown 
to reduce the time of mechanical ventilation, CPAP and supplemental oxygen and hence the 
risk of developing BPD.
113,114
 The specific mechanism by how caffeine is protective against 
lung injury remains unclear, but it has been shown to increase respiratory drive, diaphragm 
contractility, and pulmonary compliance while reducing airway resistance.
115
  
Diuretics  
To provide preterm infants adequate hydration and nutrition large fluid volumes are often 
given. Excessive fluids administered can be associated with pulmonary oedema, and in turn 
an increased need for respiratory support and an increased risk of developing BPD. Despite 
limited data regarding efficacy, diuretics are commonly used in preterm infants to improve 
respiratory status. Furosemide is a type of loop diuretics that decreases interstitial oedema 
and pulmonary vascular resistance. If used after three weeks of age furosemide improves 
oxygenation and lung compliance. However, long-term benefits have not been established 
in infants with BPD.
116
 Adverse effects with long term use are nephrocalcinosis, and loss of 
hearing.
117
 Thiazide diuretics differ from loop diuretics with respect to mechanism, mode of 
action, efficacy, and side effects. As with Furosemide it seems to have short term effects on 
pulmonary mechanics but long term effects on respiratory outcomes are unknown.
118
 
Spironolactone is a synthetic steroid that acts as a competitive aldosterone receptor 
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antagonist. Spironolactone is a weak diuretic and is primarily used in the neonatal 
population for its potassium-sparing effects, typically in combination with a thiazide 
diuretic.
117
  
Inhaled Nitric Oxide 
In animal models inhaled nitric oxide (iNO) stimulates pulmonary angiogenesis, and 
reduces inflammation and lung tissue damage.
119
 Several large randomized trials have been 
performed with diverse results
120-123
 and meta-analyses have not been able to find any long-
term improvement in incidence of BPD.
124,125
 There has been an indication that late use of 
iNO to prevent BPD could be effective, but the effect size is likely to be small.
125
 For the 
time being iNO is not recommended for routine use.
124,125
 
Vitamin A  
Vitamin A is necessary for lung growth and the integrity of epithelial cells of the 
respiratory tract. At birth Vitamin A levels are low in infants born preterm, which has been 
associated with an increased risk of BPD.
126
 A Cochrane review by Darlow et al showed an 
improved survival without BPD in neonates with a birth weight < 1000 g with vitamin A 
supplement. The results were only marginal.
127
  In a recent meta-analysis by Araki et al, a 
reduction of BPD was found in extremely low birthweight infants treated with vitamin A.
128
  
A drawback of vitamin A supplementation is that the most efficient way of administration 
is through intramuscular injection, which is painful for the infants. There are ongoing 
studies to evaluate efficacy on oral vitamin A.
129
 
 Neonatal infections 2.4.2.9
Infants born preterm are more sensitive to infections as their immune defence is not fully 
developed at birth. They have a thin, immature skin barrier, and they experience many 
invasive procedures. Chorioamnionitis increases the risk of early-onset sepsis. This leads to 
an inflammatory cascade. Late-onset sepsis also triggers a pro-inflammatory and pro-
fibrotic response.
108, 111 
Presence of microbes in lung fluid samples has been associated with 
the development of BPD.
130
 Many studies have confirmed the association between 
coagulase-negative Staphylococcus, gram-negative bacteria, ureaplasma spp and BPD 
implying that the inflammation caused by bacteria is affecting lung development.
51,131,132
 
 Factors during childhood and adolescence  2.4.3
 Asthma  2.4.3.1
Asthma is a common chronic inflammatory disorder of the airway that affects individuals 
of all ages. It usually starts in childhood and may persist into adulthood, but can develop at 
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any age. Asthma is characterized by airway obstruction and bronchial hyper- 
responsiveness. For more details see further in chapter 2.5.1. It is well known that asthma is 
not a single disease, but consists of different phenotypes with large variation in disease 
course and outcome.
133-138
 In children born preterm with and without BPD, respiratory 
symptoms are often diagnosed as asthma though in many cases non-atopic. In early 
childhood these symptoms lead to an increased hospitalization rate and increase the use of 
inhaled corticosteroids and β 2 -agonists.139, 140  Long-term follow-up of infants born <26 
weeks gestation identified that 25% had an asthma diagnosis at 11 years of age while 56 % 
had evidence of abnormal spirometry.
141
 Besides, the risk of asthma diagnosis was 
increased in children with BPD in infancy.
142
  One hypothesis is that a family history of 
asthma increases the risk for development of BPD in preterm subjects and even predicts a 
route towards the more severe forms of BPD.
143,144
 
 Physical activity 2.4.3.2
Children born preterm may be more likely to have low physical activity if they have 
impaired lung function and decreased exercise capacity. Low levels of physical activity in 
children and adolescents have been associated with future health risks, including obesity, 
metabolic and cardiovascular disease.
145
 There are few studies objectively measuring 
physical activity in children and adolescents born preterm but self-reported physical activity 
levels, especially those with BPD in infancy, have been reported to be lower than for term 
born children.
146
 The Epicure study found no differences in physical activity when 
comparing children born preterm to term born controls using accelerometers.
147
 As 
different methods have been used in the studies, comparison of results is difficult. In a 
meta-analysis on exercise capacity Edwards et al showed only a slight decrease in VO2max 
comparing preterm born children with and without BPD to term born controls.
148
 The long 
term importance of this modest reduction in work capacity remains to be further studied.  
 Infections 2.4.3.3
Several studies have shown that children who have lower respiratory tract illnesses in early 
life are at increased risk for subsequent chronic respiratory symptoms and decreased lung 
function which often persist into adult life.
149,150
 In children born preterm Montgomery et al 
reported an association of asthma diagnosis at age five and respiratory infections during 
their first year in life.
142
 Sigurs et al showed that a severe RSV infection before one year of 
age increases the risk of allergic asthma persisting into early adulthood.
151,152
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 Smoking and environmental factors 2.4.3.4
Second hand smoking (SHS) has been associated with increased respiratory symptoms and 
reduced lung function in children. It is however difficult to separate the effects of pre- and 
postnatal exposure to tobacco smoke as many mothers smoking during pregnancy continue 
to smoke after giving birth.
153
 Infants are at a greater risk of adverse effects of SHS since 
they have a high respiratory rate and immature lungs.
154
 An increased risk of hospitalization 
due to respiratory disease in low birth weight children exposed to SHS but not exposed in 
utero has been demonstrated by Chen et al.
155
 Kalliola et al showed increased FeNO levels 
and an increased airway resistance in preschool-aged children with multiple-trigger wheeze 
and exposed to SHS.
156
 In a study of older school children SHS was associated with 
reduced lung function and higher frequency of self-reported respiratory symptoms and 
respiratory infections. Lung function measured by dynamic spirometry decreased with 
increasing numbers of smokers at home and higher ozone levels.
157
 Exposure to air-
pollution during infancy has been identified as a risk factor of lower lung function in 
childhood and adolescence.
158
 The using of bio-mass fuel for cooking in the households is 
associated with more symptoms of severe asthma and lower lung function in children.
159,160
 
2.5 CHRONIC AIRWAY OBSTRUCTION IN ADULTHOOD 
 Asthma 2.5.1
Asthma is defined by the Global Initiative for Asthma (GINA) as follows: “Asthma is a 
heterogeneous disease, usually characterized by chronic airway inflammation. It is defined 
by the history of respiratory symptoms such as wheeze, shortness of breath, chest tightness 
and cough that vary over time and in intensity, together with variable expiratory airflow 
limitation”.161   
 Diagnosis 2.5.1.1
The asthma diagnosis is established based on a history of respiratory symptoms and 
confirmed variable expiratory airflow limitation. The airflow limitation is often reversible, 
either spontaneously or with treatment. Different methods to measure lung function and 
airflow limitation can be used to confirm asthma diagnosis.
161
 The recurrent episodes with 
symptoms and airflow limitation are often triggered by a variety of stimuli such as exercise, 
allergens or irritant exposure, change of weather, or respiratory infections. Symptoms may 
include wheeze, shortness of breath, chest tightness and cough, and fluctuate over time and 
in severity. More symptoms at night time and in the mornings are common. Children may 
express different symptoms compared to adults. In asthma, there should be a confirmed 
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airflow limitation including variability, assessed by clinical examination or preferable, 
measured by one or more lung function tests.
161,162
 
 Pathophysiology and immunology 2.5.1.2
The asthmatic airway inflammation includes numerous cell types, such as; mast cells, 
eosinophils, T lymphocytes, macrophages, neutrophils and epithelial cells.  
The infiltration of inflammatory cells leads to bronchial hyper-responsiveness, and in the 
case of chronic inflammation, airway remodelling.
163
 Recent molecular and genetic studies 
have identified clinical and inflammatory phenotypes that associate with specific 
biomarkers.
164
 In allergic asthma the importance of the Th2 cells is characterized by the 
contribution of the Th2 cytokines IL-4, IL-5 and IL-13 that to leads to eosinophilic 
inflammation and IgE production. Innate lymphoid cell type 2 may also contribute to the 
production of IL-5 and IL-13.
165-167
 Airway wall remodelling and repair are also important 
processes that could be driven by Th2 cytokines as well as by growth factors and cytokines 
derived from epithelial cells and macrophages.
168
 Several patients have non-eosinophilic 
asthma, sometimes associated with neutrophilic inflammation. The neutrophilic 
inflammation is believed to be driven by a pathway where Th1 and Th17 cells play an 
important role.
169
 The pathogenic mechanisms of neutrophil inflammation include an influx 
of neutrophils; IL-2, IL-8, IL-6, and IL-13 with release of interferon-γ, TNF-α, and several 
potent pro-inflammatory enzymes, such as myeloperoxidase, that cause tissue 
damage.
168,170
 A “pauci-immune” phenotype has also been described, in which neither 
eosinophils nor neutrophils are seen in airway secretions.
171 
 Chronic obstructive pulmonary disease  2.5.2
Chronic obstructive pulmonary disease (COPD) is defined by the Global Initiative for 
chronic Obstructive Lung disease (GOLD) as follows:  
“Chronic Obstructive Pulmonary Disease (COPD) is a common preventable and treatable 
disease that is characterized by persistent respiratory symptoms and airflow limitation that is 
due to airway and/or alveolar abnormalities usually caused by significant exposures to 
noxious particles or gases.”172 
An underlying chronic inflammation; that causes structural changes, destruction of the lung 
parenchyma and narrowing of the small airways, is believed to drive the disease 
progress.
172
 Tobacco smoking is the main risk factor for COPD but other environmental 
factors such as biomass fuel, air pollution, and occupational exposures may contribute.
173-
176
 Furthermore, host factors predispose individuals to develop COPD. These include 
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genetic alterations, e.g. alpha-1 antitrypsin deficiency
177
or polymorphisms in disease-
susceptibility loci
178
, infections, abnormal lung development 
179-181
, and events in early life 
such as preterm birth.
152,182-184
 Dyspnoea and cough, sometimes with sputum production, 
are the most common symptoms of COPD. Periods with worsened symptoms are called 
exacerbations. Many patients suffer from comorbidities, in particular cardiovascular 
diseases, which increases the morbidity and mortality.
185
 
  Diagnosis 2.5.2.1
The diagnosis of COPD is based on the presence of symptoms and lung function 
measurements where a post-bronchodilator spirometry ratio of forced expiratory volume in 
1 second (FEV1) ⁄ forced vital capacity (FVC) below 0.7 is required for diagnosis.
172
  The 
use of the ratio FEV1/FVC may overestimate the prevalence of COPD in elderly subjects 
and underestimate the prevalence in younger subjects.
186
 The use of lower limit of normal 
(LLN) could be helpful as a complement setting the diagnosis. The LLN is defined as the 
lower 5
th
 percentile in a representative healthy population
186-188
 COPD is further divided 
into four severity stages based on spirometry values for FEV1 (Table 2). 
Table 2. COPD severity degrees based on spirometry values according to GOLD
172
 
Basal criterion for all stages: FEV1/FVC < 0.7  
Stage Severity FEV1% of predicted 
I Mild ≥80 
II Moderate 50 - 79 
III Severe 30 - 49 
IV Very severe <30 
FEV1 and FVC are based on post bronchodilator values. Abbreviations: FEV1= forced 
expiratory flow volume in 1 second, FVC = forced vital capacity. 
  Pathophysiology 2.5.2.2
In chronic bronchitis an altered structure and function of the central airways is seen where 
the inflammation induces excessive mucus production which results in chronic cough. The 
mucus production is due to an increased number of goblet cells and enlarged submucosal 
glands caused by irritants.
189
  Chronic bronchitis is a clinical diagnosis defined by cough 
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with mucus production during more than three months a year, for two consecutive years. 
Not all patients with COPD suffer from chronic bronchitis which also is a symptom 
occurring in individuals without COPD such as “healthy” smokers.190 In bronchiolitis 
obstruction of the small airways develops. It is caused by an inflammation with repair and 
remodelling, fibrosis, thickening of the bronchial muscle layer and a production of 
exudates. Bronchiolitis results in reduction of FEV1 and FEV1/FVC ratio in patients with 
COPD. Obstruction of the smaller airways results in hyperinflation.
191,192
 The altered 
structure of the lung parenchyma with destruction of alveolar walls leads to enlarged 
alveoli, emphysema. Emphysema results in reduced gas exchange and air trapping. The loss 
of lung elastic recoil due to emphysema causes impaired exhalation and can lead to carbon 
dioxide retention.
193
 Pulmonary hypertension in COPD is due to effects on the pulmonary 
vasculature. Inflammatory cells contribute to the alterations of pulmonary vessels as well as 
hypoxia. However, pulmonary hypertension can be seen in early stages of COPD and is 
then more likely to be driven by inflammation rather than hypoxia.
194
 
 Inflammation in COPD 2.5.2.3
In COPD, a variety of exposures lead to airway inflammation where different cells and 
pathways are involved. The clinical course of COPD is partly a result of the interaction 
between the cells of the innate immune cells; such as macrophages, neutrophils and NK 
cells, and the adaptive immune system including CD8
+
 T cells, CD4
+
 T cells, and B 
cells.
18,195
  Recruitment of lymphocytes is believed to play a central role in the pathogenesis 
of COPD. In patients with COPD elevated numbers of CD8
+ 
T cells both in central and 
peripheral airways and in the lung parenchyma have been shown.
196,197
 Together with NK 
cells and NKT-like cells they damage the lung tissue through cytolytic activity.
198,199
 CD4
+ 
T cells are more common in the severe stages of disease. They act by recruiting and 
activating other immune cells and thereby maintaining the inflammatory process.
18
 
Systematic inflammation in COPD, characterised with elevated levels of circulating 
leucocytes c-reactive protein (CRP), fibrinogen, TNFα and other biomarkers, have been 
associated with muscle weakness, cardiovascular disease, cancer and osteoporosis.
200-202
 
 COPD in never-smokers 2.5.3
At least 20 % of patients with COPD are never-smokers, but less is known about this 
group.
203,204
 Since daily smoking is decreasing in the western world, COPD in never-
smokers is likely to become a larger proportion of COPD in the future. It is therefore an 
urgent need to identify groups among never-smokers that have higher risk of COPD in 
order to target prevention.
205,206
 Early life events and environmental exposures have been 
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suggested as possible causes of COPD in never-smokers, such as preterm birth, birth 
weight
207,208
, growth pattern, maternal obesity, allergen exposure, respiratory infections, 
and genetic predisposition.
182,184
 The mechanisms behind development of COPD due to 
such exposures in utero, in the neonatal period, and during childhood are still to be further 
investigated. Epigenetic studies (i.e. analyses of DNA modifications such as methylation 
that do not alter the sequence) are of high interest to explain how genes and early exposure 
might interact in the development of COPD in adulthood.
209
 Other factors through life that 
has been identified as risk for later COPD are adult asthma, air pollution exposure, biomass 
smoke
176
, occupational exposure
175
, diet, recurrent respiratory infections, and tuberculosis. 
As many of these factors vary in the world there is diversity across nations in the 
prevalence and background of non-smoking related COPD. 
152,182,210
 In the multicentre 
international Burden of Obstructive Lung Disease (BOLD) study Lamprecht et al showed 
that never-smokers comprise a substantial proportion of individuals with COPD. Increasing 
age, female sex, a prior diagnosis of asthma and lower education levels are associated with 
an increased risk.
211
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3 AIMS 
The overall aim in this thesis was:  
 To study clinical, functional and mechanistic aspects of pulmonary outcomes in 
adolescents and young adults born preterm with and without BPD. 
 
The specific objectives were:  
 To evaluate the influence of BPD severity on lung function in a cohort of adolescents 
born preterm, and to evaluate development of lung function from 7 to 14 years of age 
using longitudinal spirometry and impulse oscillometry (IOS) data (Study I). 
 To evaluate lung function and describe clinical characteristics at adult age in 
individuals born preterm with and without a prior diagnosis of BPD and compare with 
asthmatics and healthy controls (Study II).  
 To characterize the inflammatory response both systemically and in the lower airways 
in adults born preterm with and without  a history of BPD, and to compare with 
asthmatics and healthy controls (Study III).  
 To investigate immune cells from the large airways of adults born preterm with and 
without a prior diagnosis of BPD, compare with asthmatics and healthy controls, and 
evaluate potential sex differences (Study IV). 
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4 STUDY SUBJECTS AND METHODS 
4.1 STUDY SUBJECTS 
The study-subjects included in this thesis are participants in the two different cohorts 
PALM II and LUNAPRE. Some subjects belong to both cohorts (Figure 4). 
 
 
Figure 4. Schematic description of recruitment to the PALM-, PALM II-, and LUNAPRE-
studies. 
 
 Study I  4.1.1
The PALM II study cohort consisted of 51 out of 60 individuals who participated in the 
study PALM (Psychology, Allergy, Lung function and Motor development) at six to eight 
years of age.
212
 The study subjects were born before 32 weeks of GA and had been treated 
at the Neonatal Unit of Sachs’ Children’s Hospital, Stockholm, Sweden, between 1992 
to1997. Twenty-three of the participants had been diagnosed with RDS but not BPD in the 
neonatal period, and 28 were graded as mild (n=17), moderate (n=7) or severe (n=4) BPD. 
They were examined in adolescence (at13-17 years of age) using spirometry, IOS, 
plethysmography, and ergospirometry. Comparison with lung function data from childhood 
(at 6-8 years of age) was also performed.
213
 
 Study II-IV 4.1.2
The majority of the data in this thesis was conducted within the LUNAPRE cohort (LUNg 
obstruction in Adulthood of PREmaturely born; clinicaltrials.gov/ct2/show/ 
NCT02923648).
214
  The LUNAPRE cohort consists of 96 young adults, 18-23 years of age, 
born between 1989 -1998 in Stockholm County. They were included in the study between 
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2013 and 2017. There were four study groups; healthy controls, subjects with mild allergic 
asthma, and subjects born preterm ≤ GA 32 weeks with and without BPD. The healthy 
controls and the subjects with mild allergic asthma were mainly recruited from the student 
website “Studentkaninen" (http://www.studentkaninen.se/) and through open study 
advertisements. 
The LUNAPRE subjects born preterm were recruited from the PALM and PALM II 
cohorts, and from the original hospital cohort. With the exception of one person, all the 
participants in this group had been treated at the Neonatal Unit of Sachs’ Children and 
Youth Hospital, Stockholm, Sweden, between 1992 and 1998. In total, 53 individuals born 
preterm accepted participation, but four were excluded due to active smoking.  All 
participants were non-smokers and without treatment with anti-inflammatory drugs (inhaled 
corticosteroids, leukotriene receptor antagonists, antihistamine) for a period of three months 
prior to inclusion. Information on lifestyle factors, environmental exposures, symptoms and 
health outcomes were obtained by questionnaires.  Details on perinatal and neonatal history 
were collected from the Swedish Medical Birth Registry and medical charts. This included 
data on maternal smoking during pregnancy, multiple birth, caesarean section, treatment 
with prenatal steroids, Apgar score, GA at birth, BW, instillation of surfactant, number of 
days on a ventilator, CPAP and supplemental oxygen, retinopathy of prematurity (ROP) 
and patent ductus arteriosus (PDA). Small for gestational age was defined according to 
Marŝàl as -2SD.215 
 
The participants were invited to four visits for the clinical examinations including: lung 
function measurements; dynamic spirometry,  fractional exhaled NO (FeNO), IOS, multiple 
breath washout (MBW), static lung volumes, diffusing capacity for carbon monoxide 
(DLCO) and methacholine challenge test; blood sampling, urinary sampling, high resolution 
computed tomography (HRCT), echocardiography;  bronchoscopy with biopsies, bronchial 
brushings, bronchial wash,  and collection of BAL fluids (Figure 5).  
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Figure 5. Flow chart of the participants’ way though the LUNAPRE study protocol 
(study II-IV). 
4.2 METHODS  
 Questionnaires 4.2.1
Three different questionnaires were used in the LUNAPRE study. 
a) SF36 
Health-related quality of life (HRQoL) was assessed using the Swedish version of the short 
form health survey (SF)-36 (first version), a self-administered 36-item questionnaire 
covering eight different domains: physical functioning, physical role functioning, bodily 
pain, general health, vitality, social functioning, emotional role functioning, and mental 
health. Raw points are transformed into a score from 0 to 100 for each dimension, with 100 
reflecting the best possible HRQoL. The scores are summarized into two aggregated 
measures: the physical (PCS) and mental (MCS) component summary scores.
216
 
 
b) St George's Respiratory Questionnaire (SGRQ)  
SGRQ is a disease specific 50-item questionnaire designed to measure impact on overall 
health, daily life, and perceived well-being in patients with obstructive airways disease.  
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Scores are calculated for three domains: symptoms, activity and impacts (psycho-social) as 
well as a total score. A higher score means a poorer HRQoL. A minimum change in score 
of four units was established as clinically relevant after patient and clinician testing. The 
SGRQ has been used in a range of settings such as randomized controlled therapy trials and 
population surveys.
217-219
 
c) An "in-house" questionnaire designed for the LUNAPRE study with questions on 
environmental exposures, education, lifestyle, tobacco use, former and present health 
conditions, symptoms, and pharmacological treatment. 
 Lung function assessment 4.2.2
 Dynamic Spirometry 4.2.2.1
Dynamic spirometry is the most used and established lung function test in both clinical 
settings and research.  Forced vital capacity (FVC) is defined as the maximal volume of air 
exhaled with maximally forced effort from a full inspiration. Forced expiratory volume in 
one second (FEV1) is the maximal volume of air exhaled during the first second. FVC 
reflects the size of the lung and FEV1 the flow dimensions (Figure 6). The ratio FEV1/FVC 
gives an indication of the relative size of the airways compared with the lung volumes. A 
low ratio indicates airway obstruction while a high ratio implicates a restrictive pattern in 
presence of a low FVC.  
 
 
Figure 6. Dynamic spirometry volume flow loop. FEV1: Forced expiratory volume in 
one second. Reproduced from Crapo RO
220
. With permission from The New England 
Journal of Medicine.  
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A bronchodilator responsiveness test is used to evaluate the potential reversibility of an 
airway obstruction. Dynamic spirometry before and after inhalation of a β-2-agonist is 
compared, an increase of at least 12% and 200 mL in FEV1 is considered a significant 
improvement. In some cases, an improvement in FVC can also be seen as an effect of 
decreased residual volume when small airways open up.  
 
Dynamic spirometry in PALM II and LUNAPRE was measured according to American 
Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines
221
, using the 
Sensormedics 6200 body plethysmograph (SensorMedics; Yorba Linda, CA, USA). 
Examination was performed with the subject in sitting position and wearing a nose clip. 
Each subject performed at least three acceptable forced vital capacity expirations. The 
highest values of FVC and FEV1 were registered. 
 Lung volumes and diffusion capacity for carbon monoxide 4.2.2.2
Static lung volumes are measured using methods in which airflow velocity is unimportant. 
Tidal volume (VT) is the volume of air that is inhaled or exhaled with each breath. 
Inspiratory reserve volume (IRV) is the maximal volume of air that can be inhaled from the 
VT end-inspiratory level. Expiratory reserve volume (ERV) is the maximal volume of air 
that can be exhaled after a normal tidal exhalation. Residual volume (RV) is the volume of 
gas remaining in the lung at the end of a maximal expiration. Inspiratory capacity (IC) is 
the maximal volume of air that can be inhaled from the VT end-expiratory level. Vital 
capacity (VC) is the volume change between maximal inspiration and maximal expiration. 
The functional residual capacity (FRC) is the volume of air present in the lung at the end 
expiration during normal breathing. FRC can be measured by body plethysmography, gas 
washout or gas dilution tests, and by radiograph. Total lung capacity (TLC) is the volume 
of air in the lung at the end of a maximal inspiration. It is usually calculated in one of two 
ways: (1) TLC = RV + VC or (2) TLC = FRC + IC. The method of measurement (i.e., gas 
dilution, body plethysmography) should be specified (Figure 7).
222
  
 
The diffusing capacity test aims to determine the diffusion of gas between the alveoli and 
the lung capillary. The most common way to measure the diffusing capacity in the lungs 
(DL) is by using carbon monoxide (CO). The DL can be impaired due to small diffusion 
area, large diffusion way or low uptake to the blood of CO; e.g. due to low haemoglobin 
concentration. Impaired DLCO is common in patients with COPD but normal or increased in 
patients with asthma.
223
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Figure 7. Static lung volumes and capacities based on a volume-time spirogram of 
vital capacity (VC). TLC: total lung capacity, IRV: inspiratory reserve volume, TV: 
tidal volume, FRC: functional residual capacity, RV: residual volume, ERV: 
expiratory reserve volume, IC: inspiratory capacity 
 
In the studies included in this thesis, static lung volumes were measured by whole body 
plethysmography according to ATS/ERS guideines.
221,224
 In PALM II, testing took place at 
the Department of Clinical physiology, Södersjukhuset, using the Sensormedics 6200 body 
plethysmograph (SensorMedics; Yorba Linda, CA, USA). Mean values of TLC, FRC and 
RV were registered. In LUNAPRE, measurements were performed at the Department of 
Clinical physiology, Karolinska University Hospital, using the Vmax62 J CareFusion 
(SensorMedics, Yorba Linda, CA, USA). Measures included VC, FRC, TLC and RV, as 
well as DLCO. The diffusing capacity was corrected for haemoglobin levels. 
 Multiple breath washout 4.2.2.3
Inert gas washout provides information of ventilation inhomogeneity and gives information 
about small airway function. It can be performed as single breath or multiple breath 
washout (MBW). Single breath washout requires a full vital capacity breath while MBW is 
measured during tidal breathing and therefore more feasible as it needs less cooperation and 
coordination. One common and robust parameters of ventilation inhomogeneity is the lung 
clearance index (LCI) which is the number of the lung volume turnovers to clear out the 
inert gas measured to 1/40
th
 of the starting concentration. As LCI is independent of age, 
weight and height it is ideal for longitudinal monitoring both in clinic and research.
225,226
  
 
In LUNAPRE nitrogen (N2) MBW was performed using the Exhalyzer®D N2 MBWdevice 
(Eco Medics AG, Duernten, Switzerland). Two technically acceptable N2 MBW tests were 
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performed in accordance with recently published studies.
225,227
 Mean values for LCI were 
extracted. 
 Impulse Oscillometry 4.2.2.4
Involvement of the small airways may be present in lung diseases such as BPD, COPD, and 
asthma. This part of the airways is difficult to measure and is sometimes referred to as “the 
quiet zone” of the lung.228 As impulse oscillometry (IOS) only requires tidal breathing and 
no forced manoeuvers it is suitable for patients with difficulties to produce enough force 
needed for dynamic spirometry. The data obtained from IOS is thought to represent 
compound functions of the lung such as small airway obstruction and airway mechanics, 
which includes the elastic properties of the lung.
229,230
  
 
In both PALM II and LUNAPRE, assessment was accomplished using the Jaeger 
MasterScreen-IOS system (CareFusion Technologies, San Diego, CA, USA). In summary, 
pressure impulses were sent from a loudspeaker through the respiratory system. The study 
subjects were requested to breathe tidal breathing with the lips tightly sealed around the 
mouthpiece and supporting cheeks with their hands to avoid impulse pressure loss due to 
upper airway shunt. After quality inspection, the mean value of resistance at 5 and 20 hertz 
(R5, R20), frequency dependence of resistance (R5-20) and the area of reactance (AX) were 
used for analysis.
231-234
 
 Methacholine challenge test 4.2.2.5
The methacholine challenge testing is one method of assessing airway responsiveness. 
Bronchial challenge with direct stimuli, such as methacholine, is very sensitive for 
diagnosing asthma patients. Direct stimuli cause bronchoconstriction acting on the effector 
cells, such as airway smooth muscle cells, bronchial vascular endothelial cells and mucus-
producing cells. However, these stimuli lack specificity, both in differentiating asthma from 
normal and asthma from bronchial hyper-responsiveness seen in other diseases, such as 
COPD, congestive heart failure, cystic fibrosis, bronchitis, and allergic rhinitis.
235
 However, 
a negative test has a high negative predictive value and is likely to rule out asthma. The 
challenge is performed by repeated inhalations of methacholine followed by lung function 
testing. When a 20 % fall in FEV1 is achieved, the test is stopped and a concentration or 
dose is calculated and named provocative concentration (PC) or provocative dose (PD). The 
results are reported as a percent decrease in FEV1 from baseline (or post diluent if a diluent 
step is used).  A single number, PC20 or PD20, may be used to summarize the results for 
clinical purposes.
236-238
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 In LUNAPRE bronchial hyper-responsiveness to methacholine was assessed utilizing a 
Spira nebuliser (Spira Elektro 2, Respiratory Care Centre, Hämeenlinna, Finland) according 
to modified protocol
239
 at the inclusion and was the criterion used for diagnosis of 
asthma.
240
 
 Fractional exhaled nitric oxide 4.2.2.6
In respiratory epithelial cells, inflammatory cells and vascular endothelial cells nitric oxide 
is synthesized in the catalysis of nitric oxide synthase.
241
 Fractional exhaled nitric oxide 
(FeNO) is a marker of eosinophilic airway inflammation and of the total number of airway 
inflammatory cells. Elevated level of FeNO has been documented in asthma and is used 
clinically to monitor airway inflammation in asthma, and to evaluate corticosteroid 
responsiveness.
242,243
 
 
In LUNAPRE FeNO was measured with a chemiluminescence analyser (ECO MEDICS 
EXHALYZER® CLD 88sp with DENOX 88, ECO MEDICS, Dürnten, Switzerland) The 
procedure was performed in accordance with published guidelines.
244
 Mean exhalation flow 
rate was 50 mL/s ± 10% during the NO plateau. The manoeuvre was repeated until two 
exhalations agreed to within 5% coefficient of variation, or three exhalations agreed to 
within 10% coefficient of variation. The NO concentration, FeNO, was defined as the mean 
of these values expressed in parts per billion (ppb). The analyser was calibrated using a 
standard NO calibration gas (Air Liquide Deutschland GmbH, Krefeld, Germany). In a few 
study subjects FeNO was measured using a NIOX device (Aerocrine AB, Solna, 
Sweden).
245
   
 Ergospirometry 4.2.2.7
Ergospirometry is a diagnostic procedure to continuously measure respiration and gas 
metabolism during ergometer exercise. It measures the maximal oxygen consumption 
(VO2max), the amount of oxygen that is consumed for energy at maximum effort. VO2max 
is an indicator of the functional capabilities of the systems involved in the transfer of 
oxygen from the air, further from the lungs into the blood, transfer of blood to the muscles, 
and finally the use of oxygen in the muscles. It enables evaluation of function and exercise 
capacity of the cardiopulmonary system and metabolism. Ergospirometry is useful to help 
evaluate breathlessness, but also in the diagnostic process of myocardial ischemia, COPD, 
pulmonary embolism, exercise-induced asthma, unfitness, hyperventilation syndromes and 
many more.
246,247
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 In PALM II, ergospirometry was performed using an incremental Monark cycle ergometer 
(Electronic Ergomedic 839E, Monark Exercise AB, Vansbro, Sweden). The study subjects 
used a mouthpiece and wore a nose clip. Heart rate was monitored continuously. Minute 
ventilation, oxygen output (VO2) and carbon dioxide output were measured and calculated 
from a mixing chamber every 30 seconds using a SensorMedics Vmax Encore 
(SensorMedics, Yorba Linda, CA, USA). The study subjects were advised to start pedalling 
at 60-70 revolutions/min. After three minutes of unloading cycling, load was increased 
every minute by 15W. The study subjects were supported to cycle as long as possible. Peak 
values for all variables were gathered by averaging data over the last 20 seconds of 
maximum completed work. Peak VO2 in ml/kg/min was predicted using formulae for 
healthy subjects.
148,248,249
 
 Bronchoscopy and analysis of inflammatory cells 4.2.3
 Bronchoscopy 4.2.3.1
Bronchoscopy is a diagnostic procedure for routinely clinical use in several lung diseases.  
This procedure enables direct inspection and sampling of the airways. A small camera on 
the tip of the bronchoscope is used for viewing the airways, photos can be taken and 
filming can be done. Samples from the lower respiratory tract can be obtained by 
bronchoalveolar lavage (BAL). From the central airways, bronchial brushings, mucosal 
biopsies, and bronchial wash can be carried out (Figure 8).   
 
Bronchoscopy was performed in the study subjects in LUNAPRE according to a standard 
protocol.
250
 The study subjects received pre-medication to be relaxed during the procedure. 
A flexible bronchoscope was inserted into the airways through the nose. It was wedged into 
a middle lobe bronchus where five aliquots of 50 mL each of sterile phosphate-buffered 
saline solution were instilled and recollected as BAL fluid. Multiple mucosal biopsies were 
and bronchial brushings were performed from central parts of the airways. In addition, 
instillation of three portions of 10 mL phosphate-buffered saline each was performed for 
sampling of the large airways designated bronchial wash. 
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Figure 8. Bronchoscopy. Credit: The National Cancer Institute©2006 Terese Winslow, 
LLC, U.S. Govt. has certain rights 
 Analysis of inflammatory cells from bronchoalveolar lavage  4.2.3.2
The volume of BAL fluid was measured and debris and mucus were removed by filtration. 
The BAL cells were separated by centrifugation. Cell differential cell counts were 
determined on cytospin slides prepared with native pellet and stained with May-Grünwald 
Giemsa. In these cytospin slides, 500 cells were counted. Mast cells were stained with 
toluidine blue, and the number of cells within 10 visual fields (16 x magnifications) was 
scored and reported as absolute number of these cells. The cell-free BAL fluid was 
centrifuged to eliminate cell debris and the supernatant was stored at -80˚C until analysis. 
 Multicolour flow cytometry 4.2.3.3
Flow cytometry is a technique that is used for measuring many characteristics of individual 
cells in large amounts. The sample of cells in suspension passes through a laser beam under 
a laminal flow. The cells have often been labelled with fluorescent monoclonal antibody 
markers prior to infusion into the instrument. The size, the granularity and the fluorescent 
monoclonal antibody markers are absorbed by the laser beams and deflect different 
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wavelengths. A large number of cells can be measured rapidly and the data gives detailed 
information on the cell types. There are more than 350 different clusters of differentiation 
(CD) which is the international nomenclature to classify antibodies against epitopes on 
leukocytes in order to identify surface molecules. 
 
In LUNAPRE three different panels of monoclonal antibodies were used to characterize the 
major lymphocyte subsets and the T-cell differentiation subsets in BAL (Table 3).  
Lymphocyte subsets in BAL were analysed using eight colour flow cytometry (FACSCanto 
II; BD Medical, Franklin Lakes, NJ, USA). Data were processed in FACSDiva 6.1.2 (BD 
Medical). Flow cytometric data were excluded from the data analysis if fewer than 50 
events were detected in the final gate (Figure 9).  
 
Table 3. Three panels of monoclonal antibodies were used to characterize lymphocytes 
in BAL. 
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Figure 9. Representative flow cytometric dot plot of CD8
+
 (y-axis) and CD4
+
 (x-axis) 
among CD3
+
 T cells from BAL. 
 
 Analysis of inflammatory cells in bronchial wash 4.2.3.4
In order to collect cells from the large airways 3 x 10 mL phosphate-buffered saline was 
instilled during bronchoscopy in three different segments in the right upper lobe which 
immediately was recovered by gentle suction. Cells in bronchial wash were scored on 
cytospin slides stained with May-Grünwald Giemsa. 
 Peripheral blood tests 4.2.4
In LUNAPRE peripheral blood was drawn for analysis in the routine laboratory of 
Karolinska University Hospital, Solna, Sweden for white blood cells with differential 
counting, platelets, red blood cells, haemoglobin, creatinine, systemic inflammatory 
markers (acute-phase proteins: CRP, alpha-1 antitrypsin, orosmucoid, albumin and 
haptoglobin) and Phadiatop
® 
(Phadia /Thermo Fisher Scientific, Uppsala, Sweden). 
Phadiatop
® 
screens for IgE antibodies to a mix of common aeroallergens: birch, timothy, 
olive tree and mugwort, cat, dog and horse dander, mold (Cladosporium herbarum), and 
house dust mite (Dermatophagoides pteronyssinus). Additional blood samples for research 
purposes were taken at the final visit prior to bronchoscopy. 
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 Statistical analyses 4.2.5
Analyses were performed with the Stata 13.1 software package (StataCorp LP, College 
Station, TX, USA) or the SPSS 25 and Prisma 8. In all studies, a P-value <0.05 was 
considered to be statistically significant. Demographic data were presented as median and 
range for continuous variables, or numbers and percentages for categorical variables. In the 
case of non-normally distributed data, comparisons between groups were performed using 
the Wilcoxon rank-sum test for continuous variables. The Pearson’s χ-squared test was used 
for categorical outcomes. FVC, FEV1 and FEV1/FVC were converted to z-scores using the 
Global Lung Initiative reference values (GLI).
251
 The lower limit of normal was defined 
using z-scores below -1.64 (<5
th
 percentile). 
 Study I 4.2.5.1
Cross-sectional and longitudinal comparisons between groups were made using the 
Wilcoxon rank-sum test. Trends across BPD severity groups were assessed using the 
nonparametric test developed by Cuzick for trend across ordered group.252 Associations 
between other lung function outcomes and BPD severity groups were analysed using linear 
regression on the median, adjusting for sex, height and age when appropriate. The influence 
of treatment with prenatal and postnatal steroids, surfactant, ROP, PDA, necrotizing 
enterocolitis, septicaemia and maternal smoking on the relationship between BPD and lung 
function outcomes was evaluated with linear regression on the median in a univariate and 
stepwise manner. For longitudinal analysis of impulse oscillometry data, mixed models was 
used. Time-dependent covariates included in the model were height and age. BPD group 
and sex were time-invariant covariates. To assess potential variations of the effect of BPD 
on lung function over time, an interaction term between time and BPD group was included 
in the model. 
 Study II-III 4.2.5.2
Associations between BAL variables and phenotype (BPD-,  preterm-, asthma- or healthy 
control) groups were analysed using linear regression on the median, adjusting for sex, 
height, and age when appropriate 
253
. In study III, first the BPD group was compared with 
the preterm group, asthmatics and healthy controls separately. Secondly, the BPD- and 
preterm groups were combined and compared with healthy controls to evaluate overall 
associations with preterm birth regardless of BPD status. Correlations were assessed with 
Spearman’s test. Correction for multiple testing was performed with false discovery rate by 
Benjamini-Hochberg. A FDR of < 0.05 was considered statistically significant.  
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 Study IV 4.2.5.3
Comparisons between groups were evaluated by the Kruskal–Wallis test followed by the 
Mann–Whitney U test, when appropriate. Subgroup analyses for sex were performed. The 
suitable continuous variables were further analysed by the area under the curve (AUC) 
statistics for distinguishing the sub-groups. Spearman’s rank correlation was used to 
evaluate the associations of lymphocyte and eosinophils proportion with other variables.  
 
 Ethical approvals 4.2.6
All studies were approved by the Regional Ethical Review Board in Stockholm:  
Study I (PALM II): 2007/767-31/2. 
Study II-IV (LUNAPRE): 2012/11872-31/4 with amendments: 2013/1416-32 and 
2017/868-32, and by the Radiation Protection Committee Karolinska University Hospital, 
Solna K2641-2012. 
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5 RESULTS 
5.1 STUDY I 
Adolescents with a history of BPD had lower FEV1 compared to those without BPD (-0.61 
vs.-0.02 z-scores, P <0.05), with a trend for decreasing FEV1 values with increasing BPD 
severity (P for trend 0.002). Seventy-five percent of the individuals with severe BPD had 
FEV1 below the lower limit of normal (LLN; -1.64 z-scores) both in childhood and 
adolescence, and 43% of the individuals with moderate BPD (Table 4) in both time periods. 
Peripheral airway involvement in the severe BPD-group was indicated by higher frequency 
dependence of resistance, R5-20 (P <0.001 vs. non-BPD subjects). No differences between 
the groups were found for TLC or RV. There was a non significant tendency towards less 
working capacity with increasing BPD severity.  
 
 
Table 4. Percentage of individuals with spirometry measures below the lower limit of 
normal (-1.64 z-scores), at childhood and adolescence (numbers and percentage). 
 
 Between childhood and adolescence, FEV1/FVC z-scores decreased in all groups and 
particularly in the severe BPD group (from -1.68 z-scores at childhood to -2.74 z-scores at 
adolescence, P <0.05 compared to the non-BPD group (Figure10). 
 
 
 
 
 
 
  
  Childhood (7 years) Adolescence (14 years) 
  No BPD Mild 
BPD 
Moderate 
BPD 
Severe 
BPD 
No BPD Mild 
BPD 
Moderate 
BPD 
Severe 
BPD 
FEV1  0 12 (75 %) 6 (86 %) 4 (100 %) 0 3 (23 %) 2 (29 %) 4 (100 %) 
FVC 0 3 (19 %) 0 3 (75 %) 0 2 (15 %) 0 0 
FEV1/FVC  4 (17 %) 3 (19 %) 3 (43 %) 3 (75 %) 2 (10 %) 2 (15 %) 3 (43 %) 3 (75 %) 
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Figure 10. Z-scores presented as median (25
th
 and 75
th
 centiles) for FEV1/FVC at 
childhood and adolescence in mild-, moderate-, severe-, all BPD-, and non-BPD 
groups. P-values for evaluation of the evolvement from childhood to adolescence in mild, 
moderate and severe BPD groups compared to the non-BPD group. Nonparametric test for 
trend across ordered groups comparing mild-, moderate- and severe BPD-groups to the 
non-BPD group. *: P<0.05 
 
5.2 STUDY II 
Dynamic spirometry showed a significant reduction in the FEV1, FVC and FEV1/FVC ratio 
in subjects born preterm with BPD compared to all other groups (Figure 11). Further, 
ventilation inhomogeneity was indicated by an increased LCI in the BPD-group. Both 
preterm groups showed decreased DLCO compared to healthy controls and the asthma 
group.  The only difference in lung function parameters between the asthmatic and healthy 
group was a higher mean FeNO in the former.  
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Figure 11. Graphical summery of airflow, gas diffusion, ventilation inhomogeneity 
and airway inflammation. The boxplots show the median values (IQR) for FEV1, DLCO, 
LCI, and FeNO. *: p <0.05; **: p <0.01; ***:  p <0.001 
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Table 5. Proportions of subjects in each group with spirometry measures below the 
lower limit of normal (-1.64 z-scores; numbers and percentage). 
 
 
 
 
 
 
 
BPD-, preterm- and asthma-groups were compared to healthy controls. Data are presented 
as numbers (%). FEV1, FVC, and FEV1/FVC: post bronchodilator measures. *: p <0.05; 
**: p <0.01; ***:  p <0.001. Abbreviations: BPD: bronchopulmonary dysplasia; FEV1: 
forced expiratory volume in 1 s; FVC: forced vital capacity 
 
Further, in the BPD group 19 % had FEV1, and 27% had FEV1/FVC below LLN (Table 5). 
 
The asthmatic group reported more physical symptoms than the healthy control group in 
both the SF-36 and SGRQ questionnaires. The preterm group reported more physical 
symptoms than healthy control group only in the SF-36. There was no difference between 
the BPD group and the healthy controls regarding physical symptoms measured by either 
questionnaire.  Both preterm groups scored lower than healthy controls in the mental 
component of the SF-36 (Table 6).  
 
Table 6. Overview of HRQoL questionnaires.  
 Healthy Asthma Preterm BPD 
SGRQ  
Total score 
3.8 
(2.0; 6.0) 
16.5*** 
(9.2; 24.4) 
4.9 
(3.3; 8.1) 
6.3 
(3.4; 11.6) 
SF-36  
PCS (physical 
component score 
57.6 
(55.7; 58.4) 
53.5** 
(49.4; 55.1) 
52.8* 
(49.4; 54.1) 
56.3 
(53,2; 57.6) 
SF-36 
MCS (mental 
component score) 
51.7 
(48.3; 53.9) 
48.3 
(40.6; 53.2) 
44.2** 
(40.6; 52.5) 
48.2* 
(40.4; 50.8) 
BPD-, preterm-, asthma- groups were compared to healthy controls. Data are presented as 
median (IQR). *: p <0.05; **: p <0.01; ***:  p <0.001 
  
  Healthy    
n=24 
Asthma 
n=23 
Preterm 
n=23 
BPD   
n=26 
FEV1 z-scores 0 0 0 5 (19) * 
FVC z-scores 0 0 1 (4.3) 0 
FEV1/FVC z-scores 0 1 (4.3) 1 (4.3) 7 (27) ** 
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5.3  STUDY III 
No statistical differences in BAL cell differential counts were observed between the four 
study groups. The majority of cells in BAL fluid were macrophages (median 90.8% [IQR 
84.4 – 94.2]) and lymphocytes (8.0% [IQR 5.0 – 14.6]). The BPD group had a higher 
proportion of CD8
+
 T cells and a lower proportion of CD4
+
 T cells resulting in a lower 
CD4/CD8 ratio compared to healthy control group (Figure 12). The BPD group had 
increased proportion of CD69
+
CD8
+ 
T cells, i.e. activated CD8
+
 T cells when compared to 
the preterm group.  Among the CD4
+ 
T cells in BAL, effector memory cells (CD27
-
CD45RA
-
) were the dominant subset, followed by central memory cells (CD27
+
CD45RA
-
). 
The preterm group displayed lower percentages of central memory and naïve T cells 
(CD27
+
CD45RA
+
) compared to healthy controls and a higher percentage of effector T cells 
(CD27
-
CD45RA
+
) compared to the asthmatics. The BPD group had lower proportion of 
Treg (CD4
+ 
FoxP3
+
)
 
compared to the asthmatics. The proportion of NK cells (CD3
- 
CD16
+
 
and/or CD56
+
) was lower in BAL from the preterm group compared to the BPD group. 
There were no differences between the groups in the percentage of NKT-like cells (CD3
+ 
CD16
+ 
and/or CD56
+
). All groups displayed low levels of B cells. 
 
Figure 12. The dot plot show median values for CD4/CD8 ratio in BAL. **: p <0.01 
 
Further, CD4
+
 T cells correlated positively and CD8
+
 T cells negatively with expiratory 
flow rates in the preterm born subjects (Figure 13).  
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Figure 13. Correlation in both preterm groups (preterm + BPD) between CD8
+
 T cells 
(%) and FEV1 z scores. rs: Spearman rank correlation coefficient 
5.4  STUDY IV 
The total number of cells in bronchial wash did not differ between the four groups. The 
most common cell type was epithelial cells (54.8.5% [IQR 49.2-65.6] in both preterm 
groups and 61.0% [IQR 48.5-74.4] in the asthma- and healthy groups). The proportion of 
eosinophils was higher in asthmatics compared with the other three groups. The 
lymphocyte proportion in bronchial wash was elevated in the BPD group (6.6% [IQR 5.0 -
8.0]) when compared to the asthma- and healthy groups (3.4% [IQR 3.2-5.4] and 3.8% 
[IQR 2.4-4.8], respectively), as seen in Figures 14 and 15.  
 
Figure 14. Proportion of lymphocytes in bronchial wash in healthy-, asthma-, preterm 
(non BPD) - and BPD groups (%). 
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Figure 15. Micrographs of representative cytospins in healthy-, asthma-, preterm (non 
BPD) - and BPD groups. Red arrows mark the lymphocytes. 
 
There was no sex difference in the distribution of eosinophils. However, the proportions of 
lymphocytes were different in males and females. The male subjects in the BPD group had 
more lymphocytes (7.4% [IQR 6.4-8.8]), when compared with non-BPD males (5.6% [IQR 
4.2-6.3), male asthmatics (4.0% IQR 3.2-6.9) and healthy males (4.6 % [IQR 3.4-5.2]). In 
female subjects, differences in lymphocyte counts were only observed between BPD group 
and healthy group (5.8% [IQR 4.2-7.7] vs. 2.8% [IQR 2.0-3.8]). 
Lymphocyte percentage was negatively associated with z-scores of post-bronchodilator 
FEV1 and FVC only in male subjects born preterm, but not in females (Figure 16). 
 
Figure 16. Correlation between lymphocyte proportions and FEV1 in males and 
females born preterm. 
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6 DISCUSSION 
6.1 STUDY COHORTS 
The recruitment of participants to the studies was a challenge; the participating teenagers 
lived all over Stockholm and needed to take several days off from school, and the young 
adults had four separate visits to the hospitals finishing up with a bronchoscopy. Smokers 
had to be excluded as non-smoking was an inclusion criterion in order to allow the 
distinction of the impact on inflammatory cells due to preterm birth from that of the effect 
of smoking. The aim to recruit 24 subjects in each of the four study groups in LUNAPRE 
was only reached for the healthy control group. One of the unique features of the 
LUNAPRE study is the ability to make comparisons not only between groups of 
individuals born preterm with and without BPD and healthy controls, but also to a very well 
characterized control group of  patients with mild allergic asthma. To explore the 
differences and/or similarities between the pulmonary consequences of preterm birth and 
asthma, a condition of obstructive airways disease that has been well investigated for 
decades was one of the central aims of the study. In both PALM II and LUNAPRE there 
were differences in GA and BW between the two preterm groups. However, we did not see 
any differences in the outcomes when adjusting for GA and BW in the studies. Further, we 
did not see any impact of SGA on the lung function parameters which has been reported by 
others.
254,255
 My belief is that this is caused by the small sample size in our studies.  
6.2 HEALTH RELATED QUALITY OF LIFE 
The lack of differences in physical symptoms between the BPD group and healthy controls 
and more symptoms reported by asthmatics despite better lung function is to me personally 
not surprising but more confirmative and has also been demonstrated by Landry et al.
256
 
and Bozzetto et al.
257
 Young adults with a history of BPD have probably had more or less 
airway obstruction since infancy
258
 and are therefore likely to be adapted to this condition 
rather than the asthmatics who typically have acquired disease later during childhood or 
early adulthood and also might have a more variable disease. Being born preterm is 
associated with an increased risk of being diagnosed with developmental coordination 
disorder (DCD), attention deficit/ hyperactivity disorder (ADHD), attention deficit disorder 
(ADD), and autism spectrum disorder.
259-261
 This might be reflected in that the mental 
component score was lower in both preterm groups than in the healthy control group.  
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6.3 LUNG FUNCTION AFTER PRETERM BIRTH  
 Measures of airflow limitation 6.3.1
In study I we demonstrated that preterm born adolescents with BPD had lower FEV1 and 
the subjects with severe BPD also had lower FEV1/FVC compared to preterm born 
adolescents without a history of BPD (non-BPD). Thirty-eight percent of the adolescents 
with BPD had FEV1, and 33% had FEV1/FVC below LLN. This in contrast with 0% FEV1, 
and 20% FEV1/FVC below LLN in the non-BPD group. Interestingly, we showed that these 
patterns remain in young adults with a history of BPD. In study II the BPD group 
demonstrated lower FEV1, FVC and FEV1/FVC, whereas the non-BPD group showed no 
differences compared to healthy controls. The asthmatics did differ in FEV1/FVC ratio 
compared to healthy control and non-BPD groups but not to the BPD group. Nineteen 
percent of the young adults with BPD had post bronchodilator FEV1, and 27% had post 
bronchodilator FEV1/FVC below LLN. This in contrast to 0, 1 and 1% of the healthy 
controls the non-BPD group and the asthmatics, respectively. 
 
We also investigated airflow limitation in the small airways using IOS and found in 
adolescents with severe BPD signs of peripheral airway obstruction. However, in adulthood 
there were no significant differences when comparing the BPD group to the non-BPD, 
asthma and healthy control groups. Notably, we only observed the IOS differences in the 
severe BPD group in adolescence, not in all BPD groups.  
 
In study I we looked into lung development over time, from childhood to adolescence. We 
found a progress in airflow limitation measured by FEV1/FVC and frequency dependence 
of resistance (R5-20) in the severe BPD group.  The persistent changes of airflow limitation 
in adults born preterm with a history of BPD are confirmative to other studies.
256,262
  
 
Both preterm groups, in particular those with a history of BPD had a high incidence of 
airway hyper-responsiveness (AHR). AHR is a characteristic feature of asthma but also 
seen in patients with COPD. Some of the mechanisms behind AHR are considered to be 
airway inflammation, especially eosinophilic but also neutrophilic; and airway remodelling, 
including increased airway smooth muscles.
263,264
 In a systematic review and meta-analysis 
Kotecha S et al reported an increased risk of AHR in children born preterm, especially in 
children with a history of BPD. It has been noted that in children born preterm AHR is not 
associated with eosinophilic inflammation.
265
 Working capacity in children, adolescents 
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and adults born preterm has been evaluated using altering techniques in different studies 
and it is therefore difficult to compare the studies. Most studies find evidence of, or a trend 
towards, less work capacity in individuals born preterm with a history of BPD as we did in 
PALM II.
248,249
   
 Measures of lung volumes 6.3.2
We found no differences in lung volumes, measured as RV %pred. and TLC %pred. 
between the BPD and non-BPD groups in study I. In Study II the BPD group demonstrated 
reduced TLC %pred. compared to non-BPD-, asthma- and healthy control groups but RV 
%pred. and ratio RV/TLC showed no differences between the four groups. The 
alveolarization continues after birth and TLC plateaus at around 25 years of age. In study I 
we found a greater catch-up between school age and adolescence in FVC than FEV1 in the 
BPD group compared to non-BPD group. This might implicate an enhanced lung growth 
regarding the volumes but not reflected in the airways which remain more obstructive.  
 Ventilation inhomogeneity 6.3.3
Ventilation inhomogeneity measured as LCI by MBW was increased in study II in the BPD 
group compared to non-BPD-, asthma, and healthy groups. This is considered a measure of 
small airway disease and the method is commonly used in patients with cystic fibrosis. Our 
finding is congruent with a study by Caskey et al.
262
 Ventilation inhomogeneity can reflect 
areas in the lung with air-trapping due to narrowed small airways making it difficult to 
empty the inhaled air a feature also observed in obstructive lung diseases such as severe 
asthma and COPD. The asthmatics in LUNAPRE were diagnosed with mild disease and 
were therefore unlikely to show signs of air-trapping.  
 Diffusing capacity 6.3.4
In LUNAPRE a low gas diffusing capacity was observed in the BPD group, but this was 
also found in the preterm group who had normal expiratory flow volumes, confirming 
earlier findings.
262
 Diffusing capacity is not only mirroring the function of the alveoli but 
also the capillaries surrounding them. Preterm birth per se is not only affecting lung 
development, it has been suggested that a decreased microvascular surface result in lower 
DLCO also in individuals born preterm without BPD.
266
 
 FeNO, eosinophils in blood, BAL and bronchial wash 6.3.5
The asthma group was well-defined with all subjects sensitized to at least one airborne 
allergen. In the asthma group we found higher FeNO, blood eosinophils, BAL eosinophils 
 56 
 
and BW eosinophils in contrast to the BPD group who did not differ from the healthy 
control group in this respect. This indicates an eosinophilic inflammation in the airways in 
the asthma group but not in the BPD group. The BPD group was to lesser extent sensitized 
to airborne allergens. This is of importance considering the choice of pharmacological 
treatments for the patients with BPD, and could imply that they are less likely to respond to 
conventional asthma treatment such as inhaled corticosteroids.  
6.4 IMMUNE CELL PROFILES IN THE AIRWAYS AFTER PRETERM BIRTH 
 Bronchoalveolar lavage 6.4.1
LUNAPRE is to our knowledge the first study to investigate the mechanisms behind airway 
obstruction in adult individuals born preterm by bronchoscopy and BAL. We compared 
preterm subjects with an asthma patient group with airway obstruction where the 
inflammatory pattern is better known; and also to healthy never-smoking controls.  
The T-cell profiles in young adults with a history of BPD demonstrated elevated cytotoxic 
T cells (CD8
+
), decreases T-helper cells (CD4
+
) and a lower ratio CD4/CD8 which are 
features seen in patients with COPD.
267
 In the BPD group we also found indications that the 
cytotoxic T cells were activated due to a higher proportion of the early but unspecific 
marker CD 69. The correlation we found in the preterm groups between CD8
+
 T cells, 
CD4
+
 T cells and ratio CD4/CD8 and spirometry measures of airway obstruction may give 
insights about underlying disease mechanisms. The preterm born groups also demonstrated 
correlation between PD20, spirometry reversibility testing and CD8
+
 T cells and ratio 
CD4/CD8, respectively. It would be of great interest to measure markers like granzyme B 
and perforins to further confirm the action of CD8
+ 
T cells.  
 Bronchial wash 6.4.2
The pathophysiology of airways obstruction may be located in various parts of the airways. 
In order to mechanistically investigate involvement in the large airways we recruited cells 
by bronchial wash. The cell profile in the larger airway is unknown in individuals born 
preterm. Bronchial wash findings in both preterm groups with elevated lymphocytes 
indicate an involvement of both innate and adaptive immune system.
268
 As with BAL T 
cells the intraepithelial lymphocytes in bronchial wash correlated with airway obstruction, 
particularly in males. To further investigate the lymphocyte subtypes would be of high 
interest. The sex differences may suggest that there are different mechanisms related to 
long-term effects of BPD in males vs. females.
269
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7 ETHICAL CONSIDERATIONS 
Research in paediatric populations is the source of much ethical debate. There are many 
longitudinal studies that involve the collection of information as well as biological samples 
over extended periods of time. This data often spans over many years. Adolescents who are 
minor age are not independent decisions-makers and may not fully understand information 
of the research project. According to the standards for research in children, the parents or 
the legal guardian should represent the rights and the best for child in this situation. When 
the parent and child disagree (parent pro and child con), we always listen to the child´s 
opinion and do never impose any investigation without full cooperation. Furthermore, all 
collected research, data stored on computers and servers must adhere to high standards of 
security. In the PALM II and LUNAPRE cohorts we aligned the study protocols in order to 
adhere to high standards of ethical conduct. The participants were informed of their right to 
withdraw study participation at any time and without providing any motives for such 
decision. To promote data security all data referring to personal identity were coded in the 
database (which is stored on intra-net servers, protected by fire walls). Data will only be 
presented in aggregated level in publications. Furthermore, no individual data on study 
subjects is available to persons outside the study team and blood samples are stored in 
locked freezers and utilized according to standards set by Karolinska Institutet. There may 
come a time when the participants may no longer want their information to be available. In 
this case, individual level data will be expunged. In PALM II all parents and adolescents 
invited to participate received oral and written information of the procedures, and signed 
informed consent.  In LUNAPRE the participants were given oral and written information 
and all participants signed consent at the inclusion. When completing participation in 
LUNAPRE the participants received 3000 SEK as compensation for time and 
inconvenience.  This was approved by the KI ethical review board, and this type of 
incentive has been given in comparable Swedish studies. The long-term purpose with my 
research is to improve life-long health for survivors after preterm birth, today, and 
tomorrow. In the present studies, there has been little or no risk for harm, except for 
possible temporary inconvenience when collecting the data. Several participants are 
expected to benefit from the test results on an individual level, both in early detection of 
pulmonary problems of clinical significance at present, and in judging the need for future 
follow-up. 
Consider that, the advantages (improved care) with the proposed study outweigh possible 
disadvantages (integrity concerns or inconvenience). 
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8 CONCLUSIONS 
 Adolescents and young adults born very preterm with a history of BPD have 
expiratory flow values below the normal range and demonstrate hyper-responsive 
airways in adulthood. 
 
 Adolescents and young adults born preterm without a history of BPD have expiratory 
flow values in the normal range but demonstrate hyper-responsive airways in 
adulthood.  
 
 Young adults born preterm with and without a history of BPD have impaired gas 
diffusing capacity  suggesting altered lung development of the immature lung. 
 
 Young adults born preterm with a history of BPD report less symptoms than 
asthmatics despite lower lung function measures. Young adults born preterm with a 
history of BPD showed no signs of eosinophilic inflammation in the airways.  
 
 Reduced proportion of T-helper cells (CD4+), increased cytotoxic T cells (CD8+) and 
reduced CD4/CD8 ratio in young adults with a history of BPD is compatible with the 
hypothesis that T-cells play a role in development of airway obstruction in this group 
of patients and suggest similarities to what is previously described in COPD 
 
 Increased proportion of intraepithelial airway lymphocytes in adults with a history of 
BPD, particularly in males, indicate an involvement of both adaptive and innate 
immune response. The sex differences may suggest that there are different 
mechanisms related to long-term effects of BPD in males vs. females 
 
 Overall, these studies suggest that objective measurements of lung function and long 
term follow-up of patients with BPD is of  importance, and that pharmacological 
treatment needs to be tailored for this group of patients. 
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9 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Mellan 6 och 12 % av alla barn föds för tidigt, det vill säga före 37 fullföljda 
graviditetsveckor. Överlevnaden efter för tidig födsel har ökat i hela världen efter att man 
för cirka 35 år sedan introducerade rutinen att ge kortison till gravida kvinnor som löper 
risk att föda för tidigt. Dessutom har den neonatala intensivvården utvecklats och i Sverige 
överlever nu åtta av tio barn som föds extremt för tidigt, det vill säga före 28 
graviditetsveckor. Barn som föds mycket för tidigt (före 32 graviditetsveckor) löper ökad 
risk att drabbas av lungkomplikationer senare i livet. Detta beror dels på att lungorna 
mognar sent under graviditeten, dels på att det för tidigt födda barnets lungor utsätts för 
risker i form av höga luftvägs tryck från respiratorvård, syrgasbehandling och infektioner. 
Den diagnos som används för lungsjukdom på grund av för tidig födelse är 
bronkopulmonell dysplasi (BPD), vilket är ett vanligt resttillstånd efter extrem för tidig 
födelse. Då allt fler för tidigt födda barn idag överlever till vuxen ålder kommer sannolikt 
förekomsten av patienter med nedsatt lungfunktion på grund av BPD att öka framöver på 
vuxenmedicinska kliniker. Flera studier har visat att denna grupp har nedsatt lungfunktion 
redan i spädbarnsåldern och att de bär med sig funktionsnedsättningen under uppväxtåren 
upp till vuxen ålder. Många patienter uppvisar symptom som ses vid astma med en liknande 
bild vid lungfunktionsundersökning. Många patienter får också samma typ av behandling 
som patienter med astma, trots att det helt saknas behandlingsstudier. Ungefär 20-25% av 
alla vuxna patienter med kroniskt obstruktiv lungsjukdom (KOL) har aldrig rökt. I 
västvärlden minskar andelen dagligrökare, och är i Sverige nu under 10 %. Andra 
riskfaktorer än rökning för utveckling av KOL diskuteras nu, bland annat för tidig födsel 
 
Syftet med denna avhandling var att studera kliniska, funktionella och mekanistiska 
aspekter på lungsjukdom hos för tidigt födda barn, både med och utan BPD, 
frånungdomsåren och upp till ung vuxen ålder.  
 
Delarbetena i denna avhandling baserar sig på två studier, PALM II (ungdomar) och 
LUNAPRE (unga vuxna). Deltagarna i PALM II- och LUNAPRE- studierna bestod av 
individer som var mycket för tidigt födda med och utan BPD födda i Stockholm mellan 
1992 och 1998. I LUNAPRE-studien ingick också lindrigt allergiska astmatiker och friska 
kontroller. Studiedeltagarna genomgick ett flertal lungfunktionsundersökningar och i 
PALM II gjordes även ett ansträngningstest. I LUNAPRE gjordes bronkoskopi där man 
med ett böjligt instrument direkt kan inspektera luftvägarna och ta prover, både från stora 
och små luftvägar. Även blodprover togs för att undersöka tecken till inflammation och 
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allergisk sensibilisering. Deltagarna besvarade dessutom flera frågeformulär om symptom, 
hälsa, livsstil och bakgrundsfaktorer. Information om nyföddhetsperioden och 
födelseuppgifter inhämtades från journaler och från medicinska födelseregistret. 
 
Avhandlingen visar att ungdomar och unga vuxna med BPD hade luftflödesbegränsning till 
skillnad från de för tidigt födda utan BPD. Dock hade bägge grupperna en ökad känslighet i 
luftvägarna samt tecken till en nedsatt förmåga till gastransport mellan lunga och blod. 
Sammansättningen av vita blodkroppar från de små luftvägarna visade att de för tidigt 
födda med BPD hade en bild liknande den som ses hos vuxna patienter med KOL. BPD-
gruppen hade alltså en lägre andel av så kallade T-hjälparceller och en högre andel av 
cytotoxiska T-celler och ett stört förhållandet dem emellan. Vid analys av prover från de 
stora luftvägarna fann vi att patienter med BPD, främst männen hade högre andel av en 
sorts vit blodkropp, lymfocyter. Vi såg också ett samband mellan dessa celler och 
luftflödesbegränsningen. Astmatikerna i studien hade flera tecken på inflammation av 
eosinofil typ vilket är karaktäristiskt vid allergisk astma. Så var inte fallet med för tidigt 
födda individerna.  
 
För tidigt födda med BPD rapporterade mindre fysiska symptom jämfört med astmatikerna 
trots att de uppvisade mer luftflödesbegränsning.  Både de för tidigt födda, med och utan 
BPD, rapporterade sämre psykiskt välbefinnande jämfört med den friska kontrollgruppen 
 
Sammantaget visar denna avhandling att ungdomar och unga vuxna med BPD uppvisar en 
bild med luftflödesbegränsning och inflammatorisk cellbild i luftvägarna som liknar den 
som ses vid KOL. Trots detta sågs inte mer fysiska symptom än hos friska kontrollpersoner. 
Det är därför av stor vikt att följa för tidigt födda personer med BPD avseende lungfunktion 
till vuxen ålder och att studera orsakerna till luftflödesbegränsning för att i framtiden kunna 
välja lämplig behandling för dessa patienter.  
 
.   
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